Cambridge Biomarketing Honored With Multiple Industry Recognitions

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Cambridge BioMarketing, the world’s leading rare disease and specialty communications agency, today announced that it has been recognized with multiple industry accolades for its creativity and innovation in elevating the voice of the rare disease community.

PM360, the premier information resource for marketing decision makers in the pharmaceutical and medical device sectors, has named Chief Creative Officer Mike Hodgson to the 2017 PM360 ELITE 100 Creative Directors list. Now in its third year, the PM360 ELITE represents the most influential people in the healthcare industry today. Winners were formally recognized at a celebratory event last evening in New York City.

“Mike is the inspirational force that drives the unique work we do here at Cambridge BioMarketing, and his creative influence touches everything from disease awareness platforms, virtual reality conference experiences, to subway takeovers for Rare Disease Day,” said Maureen Franco, Chief Executive Officer at Cambridge BioMarketing. “We strive to constantly find new ways to provide the rare community with a voice and to bring physicians, specialists and patient communities together. We are proud to be recognized for some of the creative campaigns and tools we have designed and deployed over the past year.”

PM360 also recognized the combined marketing team of Cambridge BioMarketing and Intercept Pharmaceuticals for their work on Strengthening the PBC Patient Community, a campaign that has changed the way patients with primary biliary cholangitis (PBC) perceive themselves and pursue their healthcare. The campaign, which used patients themselves as the inspiration, included the development of an innovative app that tracks symptoms and a powerful user-generated content tool called PBC Post. The latter allows patients to send postcards to friends, family and others to express sentiments and educate around the challenges of their condition.

Medical Marketing & Media (MM&M) also named Cambridge BioMarketing a finalist in its annual awards for two categories: ‘Orphan Product Marketing Initiative’ for Cambridge BioMarketing’s work with Intercept Pharmaceuticals around Ocaliva for Welcome to Your World; and ‘Agency Self-Promotion’ for Cambridge BioMarketing for Give Pause for Some Good. These honors come on the heels of the agency being named to MM&M’s ‘Top Agencies of 2017’.

The agency was also recently recognized alongside PAN Communications for their collective efforts to promote its #SupporttheSearch campaign during this year’s annual Bell Ringer Awards. Organized by the Publicity Club of New England, the awards recognize excellence in communications and public relations work in every field and industry.

About Cambridge BioMarketing

Cambridge BioMarketing is a rare disease and specialty communications agency, blending medical insights and award-winning creativity with deep experience to build some of the world’s most successful brands. With solutions for our clients that empower, educate, and activate, we bring physicians, specialists, and patient communities together to transform human health in the face of devastating, under-appreciated disease states. Founded in 2001, Cambridge BioMarketing has offices in Cambridge, MA and Oakland CA, and is a division of Everyday Health, Inc. For more information, visit: www.cambridgebmg.com.